FDA approves Dow’s Acanya gel
WASHINGTON The Food and Drug Administration has approved Dow Pharmaceutical Sciences’ Acanya Gel, the agency announced Thursday.
The topical drug is approved for treating acne vulgaris in children and adults age 12 and older. Its active ingredients are clindamycin phosphate and benzoyl peroxide.
Dow, which specializes in topical medications, had yet to issue a statement about the approval as of midday Thursday.
Nerviano partners with Genentech to develop anticancer drugs
NEW YORK A company that develops cancer drugs has announced a multi-year collaboration with Genentech.
Nerviano Medical Sciences said that it would collaborate with South San Francisco, Calif.-based Genentech to search for antibody drug compounds to develop anticancer drugs. It is the second agreement between Genentech and NMS in less than a year, NMS said.
Genentech will have exclusive rights to fully develop and commercialize licensed products, while NMS will primarily synthesize and manufacture drug reagents.
More Americans cutting back on prescription medications
NEW YORK Economic difficulties are causing more Americans to forego prescription drugs, according to The New York Times.
Costs for housing and food are trumping costs for drugs, and some patients have stopped taking drugs for chronic conditions such as osteoporosis and high cholesterol. Some drug makers have reported decreases in sales of certain drugs, while IMS Health has reported reductions in prescriptions being dispensed.
The Times reported that the trend could cause increases in complications from chronic disease.